Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis

• Main Authors: A. Berdeli (Author), Ş. Kobak (Author)
• Format: Book
• Published: PAGEPress Publications, 2012-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.4081/reumatismo.2012.374; 0048-7449; 2240-2683
• Keywords: rheumatoid arthritis, Fas/FasL, gene polymorphism, association, manifestations; Medicine; R; Internal medicine; RC31-1245
• Source: Reumatismo, Vol 64, Iss 6, Pp 374-379 (2012)

<em>Objectives</em>. Fas/FasL is significantly involved in the pathogenesis of rheumatoid arthritis (RA). Fas/FasL gene polymorphism may be associated with susceptibility to rheumatoid arthritis and disease severity. <em>Aim</em>. To investigate the Fas 670 G/A and FasL 843 C/T genotype and allele frequency in patients with RA, and determine its potential association with susceptibility to the disease and the clinical parameters. <em>Methods</em>. One hundred and one patients with RA and 105 healthy control subjects were enrolled in the study. Fas 670 A/G and FasL 843C/T genotype polymorphism was investigated by PCR-RFLP. Chi-square test was used for determining the genotype distribution and the allele incidence. <em>Results</em>. There was no statistically significant difference between the patients with RA and the healthy subjects with respect to Fas-670 A/G and FasL-843C/T genotype distribution and allele frequency (P>0.05). While there was no statistically significant difference in disease severity and various clinical parameters, a correlation was detected between Fas-670 polymorphism and anti-CCP antibody and anemia (P<0.01 and P<0.03, respectively). <em>Conclusions</em>. Fas-670A/G and FasL-843C/T promoter gene polymorphisms are not considered to represent a major genetic risk factor for RA susceptibility and disease severity. However, based on these results, Fas-670 promoter polymorphism may modulate anti-CCP antibody synthesis and response in patients with rheumatoid arthritis.